ArticleEuropean journal of nuclear medicine and molecular imaging2023
Additive value of [
Article in European journal of nuclear medicine and molecular imaging, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.
- Pooled it
- Stage-dependent tau-PET signatures in Huntington's disease revealed by [¹⁸F]PI-2620.European journal of nuclear medicine and molecular imaging · 2026Article
- Dynamic [Molecular neurodegeneration · 2026Article
- Tau conformation, distribution and PET imaging correlations in progressive supranuclear palsy.Translational neurodegeneration · 2026Review
- Neuroimaging and Pathology Biomarkers in Parkinson's Disease and Parkinsonism.Brain sciences · 2026Article
- Additive value of early-phase β-Amyloid-PET for the differential diagnosis of non-Alzheimer's disease dementia.NeuroImage. Clinical · 2026Article
- From clinical phenotypes to molecular stratification: early differential diagnosis of four-repeat tauopathies.Frontiers in aging neuroscience · 2026Review
- Developing a novel reference region for [European journal of nuclear medicine and molecular imaging · 2025Article
- Neuronal and oligodendroglial, but not astroglial, tau translates to in vivo tau PET signals in individuals with primary tauopathies.Acta neuropathologica · 2024Article
- Combining cerebrospinal fluid and PI-2620 tau-PET for biomarker-based stratification of Alzheimer's disease and 4R-tauopathies.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- Tau aggregation following subcortical hemorrhage.European journal of nuclear medicine and molecular imaging · 2024Article
- Tau accumulation is associated with dopamine deficiency in vivo in four-repeat tauopathies.European journal of nuclear medicine and molecular imaging · 2024Article
- Progressive Supranuclear Palsy: Subcortical Tau Depositions Are Associated with Cortical Perfusion in Frontal and Limbic Regions.Journal of Parkinson's disease · 2024Article
- Boundary-based registration improves sensitivity for detecting hypoperfusion in sporadic frontotemporal lobar degeneration.Frontiers in neurology · 2024Article
- [18F]PI-2620 Tau PET signal across the aging and Alzheimer's disease clinical spectrum.Imaging neuroscience (Cambridge, Mass.) · 2024Article
- Individual regional associations between Aβ-, tau- and neurodegeneration (ATN) with microglial activation in patients with primary and secondary tauopathies.Molecular psychiatry · 2023Article
- Application of Deep Learning for Prediction of Alzheimer's Disease in PET/MR Imaging.Bioengineering (Basel, Switzerland) · 2023Review
- Pathomechanisms of cognitive impairment in progressive supranuclear palsy.Journal of neural transmission (Vienna, Austria : 1996) · 2023Review
Corrections and comments
- Comment on
Authors and funding
49 authors at 12 institutions in 4 countries.
Funding
Abstract
purposeEarly after [
methodsSeventy-eight patients with 4RTs (71 ± 7 years, 39 female), 79 patients with other neurodegenerative diseases (67 ± 12 years, 35 female) and twelve age-matched controls (69 ± 8 years, 8 female) underwent dynamic (0-60 min) [
resultsPatients with 4RTs had significant hypoperfusion in 21/246 brain regions, most dominant in thalamus, caudate nucleus, and anterior cingulate cortex, fitting to the topology of the 4RT disease spectrum. However, single region hypoperfusion was not specific regarding the discrimination of patients with 4RTs against patients with other neurodegenerative diseases. In contrast, perfusion pattern expression showed promise for discrimination of patients with 4RTs from other neurodegenerative diseases (AUC: 0.850). Discrimination by the combined perfusion-tau pattern expression (AUC: 0.903) exceeded that of the sole tau pattern expression (AUC: 0.864) and the discriminatory power of the combined perfusion-tau pattern expression was replicated in the external dataset (AUC: 0.917). Perfusion but not tau pattern expression was associated with PSP rating scale (R = 0.402; p = 0.0012) and activities of daily living (R = - 0.431; p = 0.0005).
conclusion[
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.